BeiGene
BeOne Medicines (formerly BeiGene) is a global oncology company developing and commercializing BRUKINSA, TEVIMBRA, and BEQALZI across 80+ markets, with proprietary protein degradation (CDAC) and ADC platforms and a deep hematology and solid tumor pipeline.
- Company typePublic
- Founded2010
- HeadquartersCambridge, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What BeiGene does
BeOne Medicines I GmbH, operating as BeOne Medicines and formerly known as BeiGene, is a global oncology company founded in 2010 and headquartered in Basel, Switzerland (with major operations in Beijing and San Mateo). The company is dual-listed on NASDAQ (ticker ONC), HKEX, and the Shanghai Stock Exchange and markets three approved cancer medicines: BRUKINSA (zanubrutinib), the leading global BTK inhibitor approved in more than 80 markets and generating $3.9 billion in FY2025 sales at 49% year-over-year growth; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved in multiple solid tumor indications; and BEQALZI (sonrotoclax), the first and only FDA-approved BCL2 inhibitor for B-cell malignancies, approved in May 2026.
The company's pipeline spans hematology and solid tumors and includes BTK degraders (BGB-16673/tacabrutideg), a CDK4 inhibitor entering Phase 3 for first-line metastatic breast cancer, the anti-TIGIT antibody ociperlimab, the HPK1 inhibitor BGB-26808, the PRMT5 inhibitor BGB-58067, and the GPC3×4-1BB bispecific BGB-B2033. Underlying these programs are two proprietary technology platforms: CDAC (Conditionally Active Biodegradable Antibody Conjugates), a protein degradation modality, and an enhanced Antibody Drug Conjugate (ADC) platform. Clinical differentiation is anchored by long-duration efficacy data, including 71.8% progression-free survival at 78-month follow-up in CLL/SLL (SEQUOIA trial) and an 85.1% overall response rate for the BTK degrader in heavily pretreated relapsed/refractory CLL.
BeOne Medicines operates a hybrid commercial model: direct sales infrastructure across more than 80 markets including the US, EU, and China, supplemented by licensing partnerships such as the Glenmark deal for emerging markets and the Jazz Pharmaceuticals collaboration on zanidatamab (Ziihera). FY2025 product revenue reached $5.3 billion (40% year-over-year growth) at 88% gross margin, generating the company's first full-year GAAP net profit of $287 million and more than $940 million in free cash flow. Amgen holds an approximately 20.5% equity stake acquired in 2020.
BeiGene firmographics
Firmographics- Name
- BeiGene
- Legal name
- BeOne Medicines I GmbH
- Website
- https://beigene.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- BeOne Medicines (formerly BeiGene) is a global oncology company developing and commercializing BRUKINSA, TEVIMBRA, and BEQALZI across 80+ markets, with proprietary protein degradation (CDAC) and ADC platforms and a deep hematology and solid tumor pipeline.
- Ownership category
- akta.pro rank
BeiGene industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where BeiGene is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BeiGene business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Revenue - BRUKINSA: BRUKINSA (zanubrutinib) is the company's flagship BTK inhibitor generating $3.9 billion in global sales in FY2025, representing 49% year-over-year growth. The drug is approved in 80 markets and maintains position as the leading BTK inhibitor globally. BRUKINSA generated $1.1 billion in Q4 2025 and is on track to generate approximately $5 billion in revenue in 2026.
- Product Revenue - Tevimbra: Tevimbra (tislelizumab) is the company's PD-1 inhibitor generating $206 million in Q1 2026 revenue, 7% above analyst estimates. The drug is approved in multiple indications and received priority review from US FDA for first-line HER2+ gastroesophageal adenocarcinoma.
- Product Revenue - BEQALZI (sonrotoclax): BEQALZI (sonrotoclax) received FDA approval in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies, representing a new revenue stream for the company. The drug has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.
- Partnership Revenue - Zanidatamab/Ziihera: BeOne Medicines partnered with Zymeworks on zanidatamab (Ziihera), which received FDA approval for biliary tract cancer and is being developed for HER2-positive gastroesophageal adenocarcinoma. The partnership includes milestone payments and royalty streams, with Jazz Pharmaceuticals collaborating on commercialization.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
BeiGene product offering
Product offeringCore offering
BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes proprietary cancer therapeutics. Its portfolio spans approved drugs (BRUKINSA BTK inhibitor, TEVIMBRA PD-1 inhibitor, BEQALZI BCL2 inhibitor) for hematologic malignancies and solid tumors, plus a deep pipeline of investigational BTK degraders, bispecific antibodies, CDK4/PRMT5/HPK1 inhibitors and TIGIT antibodies. The company operates direct commercial infrastructure across 80+ markets and licenses products in emerging geographies to broaden patient access.
Product overview
BeOne Medicines (BeiGene) is a global oncology company developing a broad portfolio of cancer medicines. The company's approved products include BRUKINSA (zanubrutinib), a leading BTK inhibitor approved in over 80 markets for B-cell malignancies; TEVIMBRA (tislelizumab), a PD-1 inhibitor for various solid tumors; and BEQALZI (sonrotoclax), a BCL2 inhibitor approved in May 2026. The pipeline includes investigational BTK degraders (BGB-16673, tacabrutideg), a PRMT5 inhibitor (BGB-58067), a bispecific antibody (BGB-B2033), a TIGIT inhibitor (ociperlimab), an HPK1 inhibitor (BGB-26808), and a CDK4 inhibitor in Phase 3 development. The company also develops proprietary technology platforms including CDAC (protein degradation) and ADC (antibody drug conjugates). Research focuses on hematology (blood cancers) and solid tumors (breast, gynecologic, gastrointestinal, lung, liver cancers).
Differentiator
Problem solved
Functional benefit
Products and services
- BRUKINSA (zanubrutinib) Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. BRUKINSA is the leading BTK inhibitor globally, approved in 80+ markets, and generated $3.9B in FY2025 sales with 49% YoY growth.
- TEVIMBRA (tislelizumab) Anti-PD-1 monoclonal antibody approved in multiple indications for the treatment of various solid tumors, including lung cancer and HER2-positive gastroesophageal adenocarcinoma. TEVIMBRA generated $206 million in Q1 2026 revenue and has received U.S. FDA Priority Review for first-line HER2+ GEA.
- BEQALZI (sonrotoclax) Next-generation BCL2 inhibitor approved by the U.S. FDA in May 2026 as the first and only BCL2 inhibitor for certain B-cell malignancies. Demonstrated 100% ORR with 59.5% complete responses in treatment-naive CLL patients and has also received Breakthrough Therapy Designation for relapsed or refractory mantle cell lymphoma.
- Ziihera (zanidatamab) HER2-targeted bispecific antibody partnered with Zymeworks and co-commercialized with Jazz Pharmaceuticals for HER2-positive cancers. Approved for biliary tract cancer with positive Phase 3 data in gastroesophageal adenocarcinoma; eligible for up to $1.5 billion in potential milestone payments.
Quantifiable outcome
- 74% progression-free survival at 6 years in treatment-naïve CLL patients with BRUKINSA
- +5 more outcomes
Companies that use BeiGene
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
BeiGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
BeiGene partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Blood Cancer UnitedcoreExpanded multi-year partnership announced June 2026 with BeOne committing US$5,000,000 over three years to support patient education, community engagement, and the blood cancer care continuum. Reinforces BeOne's hematology narrative and patient-centric approach.
- GlenmarkcoreGlenmark signed billion-dollar licensing deals with BeiGene to commercialize lung cancer and other oncology drugs across emerging markets. Treatments offered at ₹50,000 per session compared to ₹200,000-500,000 for Western alternatives, significantly expanding patient access.
- Ensem TherapeuticsminorStrategic licensing collaboration for CDK2 inhibitor development targeting RAS-mutated tumors, part of BeOne's shift toward personalized and precision medicine approaches in prostate cancer and other solid tumors.
- ZymeworkscorePartnership on zanidatamab (Ziihera) for HER2-positive cancers. Positive Phase 3 data in gastroesophageal adenocarcinoma showed significant improvements in PFS and OS. Ziihera approved for biliary tract cancer with PDUFA date August 25, 2026 for GEA.
- Jazz PharmaceuticalscoreJazz Pharmaceuticals collaborating on commercialization of zanidatamab in HER2-positive gastroesophageal adenocarcinoma. Expects FDA approval and market launch in second half of 2026 with up to $1.5 billion in potential milestone payments from collaboration.
Scale indicators12 records
Recent moves6 records
Expansion highlights7 records
BeiGene competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
BeiGene social profiles
Digital presenceBeiGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
BeiGene leadership team
Management profileNumber of profiles
Profiles10 records
BeiGene funding detail
Funding detailFunding overview
Funding rounds7 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BeiGene M&A and investment
M&A and investmentM&A
Investments9 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BeiGene
What does BeiGene do?
BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes proprietary cancer therapeutics. Its portfolio spans approved drugs (BRUKINSA BTK inhibitor, TEVIMBRA PD-1 inhibitor, BEQALZI BCL2 inhibitor) for hematologic malignancies and solid tumors, plus a deep pipeline of investigational BTK degraders, bispecific antibodies, CDK4/PRMT5/HPK1 inhibitors and TIGIT antibodies. The company operates direct commercial infrastructure across 80+ markets and licenses products in emerging geographies to broaden patient access.
Is BeiGene a public or private company?
BeiGene is a public company. It is classified as public and is currently operating.
When was BeiGene founded?
BeiGene was founded in 2010. It employs 5,001 to 10,000 people.
Where is BeiGene based?
BeiGene is headquartered in Cambridge, United States, in the North America region.
How does BeiGene make money?
Four revenue lines are on record. Product Revenue - BRUKINSA is the primary driver. The others are product Revenue - Tevimbra, product Revenue - BEQALZI (sonrotoclax) and partnership Revenue - Zanidatamab/Ziihera.
Does BeiGene have an API?
No public API is recorded for BeiGene.
What industry is BeiGene in?
BeiGene's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.